Jiebai-Qingfei San Protects Against Lipopolysaccharide-Induced Acute Lung Injury by Modulating Inflammation, Oxidative Stress, and Macrophage-Associated Phenotypes
Pharmaceuticals · 18.11.2026 · 19 (11) · 1835
DOI: 10.3390/ph19111835 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 18.11.2026. Verfasst von Xiangwen Deng und 6 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, National Key Research and Development Program.
Abstract (Originalsprache)
Background
Jiebai-Qingfei San (JBQFS) is a seven-herb traditional Chinese veterinary formulation developed for respiratory disorders. However, its pharmacological effects against acute pulmonary inflammation and the associated molecular responses remain unclear. This study examined the protective activity of JBQFS in LPS-induced acute lung injury (ALI) and characterized the biological responses associated with treatment.
Methods
The chemical profile of JBQFS was characterized by ultra-high-performance liquid chromatography coupled with high-resolution tandem mass spectrometry (UHPLC-HRMS/MS), and two representative marker compounds were quantified by high-performance liquid chromatography (HPLC). Lung transcriptomic analysis followed by qRT-PCR validation was performed to identify inflammation-related transcriptional responses. The effects of JBQFS were further examined in the murine alveolar macrophage cell line MH-S following LPS stimulation.
Results
JBQFS pretreatment ameliorated LPS-induced alterations in respiratory parameters and attenuated histopathological injury, reduced inflammatory cytokine levels, and improved oxidative stress-related parameters. It also modulated macrophage-associated markers in lung tissue. Transcriptomic and qRT-PCR analyses showed that JBQFS administration was associated with changes in inflammation-related transcriptional responses, including genes related to TLR4/MyD88/NF-κB signaling. In MH-S cells, JBQFS reduced inflammatory mediator production and intracellular ROS and Ca2+ levels, preserved mitochondrial membrane potential, and modulated CD80, CD86, and CD206 expression.
Conclusions
Pretreatment with JBQFS protected against LPS-induced ALI and was associated with reduced inflammation and oxidative stress, as well as modulation of macrophage-associated inflammatory phenotypes. These findings support further investigation of JBQFS for inflammatory respiratory disorders.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- National Key Research and Development Program
Zitieren
APA
Deng, X., He, J., Yu, L., Yu, Y., Fang, K., Yang, Y., & Wang, D. (2026). Jiebai-Qingfei San Protects Against Lipopolysaccharide-Induced Acute Lung Injury by Modulating Inflammation, Oxidative Stress, and Macrophage-Associated Phenotypes. Pharmaceuticals, 19(11), 1835. https://doi.org/10.3390/ph19111835
Vancouver
Deng X, He J, Yu L, Yu Y, Fang K, Yang Y, et al. Jiebai-Qingfei San Protects Against Lipopolysaccharide-Induced Acute Lung Injury by Modulating Inflammation, Oxidative Stress, and Macrophage-Associated Phenotypes. Pharmaceuticals. 2026;19(11):1835. doi:10.3390/ph19111835
BibTeX
@article{Deng2026,
author = {Deng, Xiangwen and He, Jin and Yu, Lin and Yu, Yaming and Fang, Kexin and Yang, Yang and Wang, Deyun},
title = {Jiebai-Qingfei San Protects Against Lipopolysaccharide-Induced Acute Lung Injury by Modulating Inflammation, Oxidative Stress, and Macrophage-Associated Phenotypes},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1835},
doi = {10.3390/ph19111835}
}
EUVIMED